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Background
Cellular cGMP effects can be mediated by a number of
effectors including cGMP-dependent protein kinases
(PKGs), cGMP-stimulated phosphodiesterase (PDE2),
cGMP-inhibited phosphodiesterase (PDE3), and cGMP-
gated channels. Pharmacological inhibitors of PKG are
often used to discriminate between these diverse cGMP
effects. Currently used PKG inhibitors can be divided
into three classes: cyclic nucleotide binding site inhibitors
like Rp-phosphorothioate analogs, ATP binding site inhi-
bitors like KT5823, and substrate binding site inhibitors
like the recently described DT-oligopeptides. However,
several studies have observed no PKG inhibition by
KT5823 in intact cells [1] or by Rp-cGMPS analogs in
smooth muscle cells [2], as well as unspecific (PKG-inde-
pendent) effects of Rp-cGMPS analogs in platelets [3].
Results
We tested the inhibitory effects of (D)-DT2 and DT3 on
PKG and its effects on intact cells. Our data show that
(D)-DT2 selectively inhibited 2 nM purified PKG Ia and
Ib with an IC50 o f8n M ,a n dt h a tu pt o1µ M( D ) - D T 2
did not inhibit PKG II or PKA. In broken platelet cell
experiments, PKG activity was inhibited by (D)-DT2
starting at 5 µM, with complete inhibition at 20 µM,
but we also observed inhibition of PKA activity at these
concentrations. However, concentrations of up to 200
µM of compounds failed to inhibit PKG activity
(assessed by phosphorylation of the established PKG
substrates VASP, PDE5 and GRP2) in intact human pla-
telets, rat mesangial cells and neonatal mouse cardiac
myocytes. It should be noted that the measured PKG
concentration is about 7 µM in platelets and 0.1 – 0.5
µM in all other tested cells. (D)-DT2 effects on platelet
function did not correlate with PKG activity.
Preincubation of platelets with 10 nM (D)-DT2 strongly
inhibited thrombin-induced platelet aggregation and cal-
cium mobilization, whereas it potentiated these effects
in collagen-stimulated platelets.
Conclusion
Interpretations of results based on PKG inhibitors
require caution. None of the commercially available
PKG inhibitors should be used without control experi-
ments in intact cells since they may have unpredictable
functional effects not mediated by PKG activity.
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